Market Size of Hypogonadism Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hypogonadism Treatment Market Analysis
The Hypogonadism Treatment Market is expected to register a CAGR of 3% during the forecast period attributing to increase in the incidence of hypogonadism, a rise in awareness about the disease and its treatment options and growth of infertility rate. Moreover, high risk of hypogonadism in the geriatric population and patient pool with diabetes and obesity are also some of the key drivers in the hypogonadism treatment market. For instance, according to a report published by the National Institute of Health (NIH), in 2019 obesity is increasing worldwide and the prevalence of hypogonadism is significantly greater in males with obesity. In addition, men aged between 60-80 years have low testosterone levels by 20% and 80% than normal testosterone levels in young men. Men above 60 years have the highest prevalence of hypogonadism. Thus, countries surging the geriatric population are witnessing a high demand for therapies to treat hypogonadism, hence, driving the hypogonadism market.
Hypogonadism Treatment Industry Segmentation
Hypogonadism is a rare hormonal disorder characterized by insufficient production of testes or ovaries, result in diminished production of sex hormones. Hypogonadism Treatment Market is segmented By Type, Treatment Type, Route of Administration and Geography.
| By Type | |
| Primary Hypogonadism | |
| Central Hypogonadism |
| By Treatment Type | |
| Testosterone Replacement Therapy | |
| Estrogen Therapy | |
| Progesterone Therapy |
| By Route of Administration | |
| Topical Gel | |
| Transdermal Patch | |
| Implantable Pellet | |
| Oral Tablets | |
| Others |
| By End User | |
| Hospitals | |
| Speciality Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hypogonadism Treatment Market Size Summary
The hypogonadism treatment market is poised for steady growth, driven by an increasing incidence of the condition, heightened awareness of its treatment options, and a rising infertility rate. The market is further propelled by the high prevalence of hypogonadism among the geriatric population and individuals with diabetes and obesity. The condition is notably more common in older men, particularly those aged 60 to 80, and in those with obesity, which is contributing to the demand for effective therapies. Testosterone replacement therapy is anticipated to be the primary revenue contributor, supported by government initiatives and product approvals, such as those by Clarus Therapeutics and Antares Pharma. The declining fertility rates are also linked to the rising incidence of hypogonadism, thereby fostering market growth.
North America is expected to maintain its dominance in the global hypogonadism treatment market, attributed to the increasing prevalence of the condition, greater awareness, and the adoption of advanced healthcare solutions. The region's robust healthcare infrastructure supports this growth trajectory. The market is characterized by moderate competition, with several international companies like Abbott Laboratories, Eli Lilly, Teva Pharmaceutical Industries, Endo International, Ferring Pharmaceuticals, AbbVie, and Merck Serono actively participating. These companies are instrumental in driving innovation and expanding the availability of treatment options, thereby shaping the market landscape during the forecast period.
Hypogonadism Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 High Risk of Hypogonadism in Geriatric Population
-
1.2.2 Lifestyle Issues
-
-
1.3 Market Restraints
-
1.3.1 Social Taboo
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 Primary Hypogonadism
-
2.1.2 Central Hypogonadism
-
-
2.2 By Treatment Type
-
2.2.1 Testosterone Replacement Therapy
-
2.2.2 Estrogen Therapy
-
2.2.3 Progesterone Therapy
-
-
2.3 By Route of Administration
-
2.3.1 Topical Gel
-
2.3.2 Transdermal Patch
-
2.3.3 Implantable Pellet
-
2.3.4 Oral Tablets
-
2.3.5 Others
-
-
2.4 By End User
-
2.4.1 Hospitals
-
2.4.2 Speciality Clinics
-
2.4.3 Others
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle-East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle-East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Hypogonadism Treatment Market Size FAQs
What is the current Hypogonadism Treatment Market size?
The Hypogonadism Treatment Market is projected to register a CAGR of 3% during the forecast period (2024-2029)
Who are the key players in Hypogonadism Treatment Market?
Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International and Ferring Pharmaceuticals are the major companies operating in the Hypogonadism Treatment Market.
